| Literature DB >> 33802391 |
Lea M Monday1, Tommy Parraga Acosta1, George Alangaden1,2.
Abstract
Invasive candidiasis is a common healthcare-associated infection with high mortality and is difficult to diagnose due to nonspecific symptoms and limitations of culture based diagnostic methods. T2Candida, based on T2 magnetic resonance technology, is FDA approved for the diagnosis of candidemia and can rapidly detect the five most commonly isolated Candida sp. in approximately 5 h directly from whole blood. We discuss the preclinical and clinical studies of T2Candida for the diagnosis of candidemia and review the current literature on its use in deep-seated candidiasis, its role in patient management and prognosis, clinical utility in unique populations and non-blood specimens, and as an antifungal stewardship tool. Lastly, we summarize the strengths and limitations of this promising nonculture-based diagnostic test.Entities:
Keywords: T2Candida; candidemia; fungemia; invasive candidiasis
Year: 2021 PMID: 33802391 PMCID: PMC7999352 DOI: 10.3390/jof7030178
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X